• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Beijing Airdoc Technology (SEHK:2251) Stock Faces Widening Losses Behind Premium Valuation

    Simply Wall St·08/30/2026 22:28:56
    Listen to the news

    Beijing Airdoc Technology walked into this earnings day with a stock that had already slipped over the past week and quarter. Yet the real story now is how the income statement pressure clashes with that premium valuation. The headline is the profit squeeze. First half 2026 revenue came in at ¥67.3m while the company booked a net loss of ¥48.9m and basic earnings per share of a ¥0.48 loss.

    For a healthcare technology stock trading on a P/S of 5.3x, above industry and peer averages, that mix of shrinking share price and sustained losses is exactly where sentiment is being tested.

    Like the Beijing Airdoc Technology story but wary of paying a premium P/S multiple for a stock that is still reporting losses? You may want to compare it with other healthcare and AI focused businesses that pair growth potential with stronger balance sheets in our list of solid balance sheet and fundamentals stocks (429 results).

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs. H1 2025): ¥67.291m vs. ¥83.713m (decline of 19.6%)
    • Net Loss, Excluding Extra Items (H1 2026 vs. H1 2025): ¥48.852m loss vs. ¥1.673m loss (loss widened by 1,818.1%)
    • Basic EPS (H1 2026 vs. H1 2025): ¥0.48 loss per share vs. ¥0.016475 loss per share (loss per share increased by 1,813.6%)
    • Trailing 12 Month Revenue (TTM to H1 2026 vs. TTM to H1 2025): ¥156.84m vs. ¥146.37m (increase of 7.2%)

    If you prefer clear visual charts instead of extensive financial tables and footnotes, view Beijing Airdoc Technology's complete financial profile and valuation in our company report for Beijing Airdoc Technology.

    SEHK:2251 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    SEHK:2251 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Beijing Airdoc: Gauging Support For The Bullish Story

    For anyone backing Beijing Airdoc as an AI healthcare platform, the latest numbers send a mixed but not entirely negative message. Trailing 12 month revenue of ¥156.84m is higher than the prior 12 month period, which at least keeps the topline moving in the right direction for a commercialising technology story. That said, the H1 2026 revenue drop to ¥67.3m and the much larger loss of ¥48.9m show that scaling the model is proving costly and that profitability is moving further away for now.

    Beijing Airdoc: Testing The Bearish Concerns

    Bearish investors focused on execution risk will see the H1 2026 set as support for their concerns. Revenue fell 19.6% year on year, while the net loss excluding extra items widened very sharply to ¥48.9m. Basic EPS also moved deeper into loss territory. That combination of shrinking period revenue and a larger loss suggests Beijing Airdoc is under pressure to control costs or reignite growth to justify continued investment in its AI driven healthcare products.

    With Beijing Airdoc Technology still loss making and trading on a premium P/S multiple, it is important to assess whether the balance sheet can absorb more cash burn without potentially dilutive funding moves. Check the detailed solvency and liquidity picture in our financial health analysis of Beijing Airdoc Technology stock.

    Stay Ahead With Simply Wall St

    If Beijing Airdoc Technology's premium P/S and widening losses have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. After you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key updates that actually matter for your holdings. For a bigger picture view, tap into thousands of investor insights through the Community and see how others are thinking about similar risks and opportunities. This way you can spot potential catalysts and red flags early and stay a step ahead of the market.

    Seeking Alternatives Beyond Beijing Airdoc?

    Fresh stock ideas can move from quiet potential to full breakout quickly. Use the momentum while it matters and, before they stop flying under the radar, consider getting in early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.